Chemomab Therapeutics

About Chemomab Therapeutics

Chemomab (Nasdaq: CMMB) is a clinical-stage biotech firm specializing in fibro-inflammatory disorders. In 2026, their lead candidate, CM-101, is advancing through three parallel Phase 2 trials, targeting a novel and differentiated mechanism of action that interferes with the underlying biology of liver, skin, and lung fibrosis.